查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771719

mRNA治疗合约开发与受託製造厂商市场规模、份额、趋势分析报告：按适应症、应用、最终用途、地区、细分市场预测，2025-2033年

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Metabolic & Genetic Diseases), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10个工作天内

价格

mRNA 治疗合约开发和受託製造厂商市场的成长和趋势

根据 Grand View Research, Inc. 的新报告，全球 mRNA 疗法合约开发和受託製造厂商市场预计到 2033 年将达到 147.5 亿美元，2025 年至 2033 年的复合年增长率为 15.22%。

mRNA 和细胞递送系统技术日新月异，加之其成本效益高、易于生产以及能够靶向此前无法治癒的途径，拥有无限潜力，有望彻底改变医疗保健行业。这对市场而言可能是一个利润丰厚的成长机会。不断增加的研发投入用于开发 mRNA 疗法以及强大的产品平臺也推动市场的成长。例如，Moderna 宣布其 2023 年第四季的研发费用达到 14 亿美元，较 2022 年同期成长 16%。

研发费用的成长主要源自于公司巨细胞病毒(CMV) 疫苗、呼吸道合胞病毒 (RSV) 疫苗、新冠肺炎 (COVID-19) 和流感联合疫苗以及个人化肿瘤抗原治疗的临床生产活动增加。这些因素预计将推动 mRNA 疗法的研究力度。此外，为满足尚未满足的医疗需求而开发的新型疗法正在改变产品市场。随着分子复杂性的增加，对研发和生产服务的深度了解，以及能够实现新型分子形式可持续表达和规模化生产的技术的需求日益增长。生物偶联和双特异性抗体生成等平台技术可以显着缩短开发和生产时间，客户正在寻求能够加快产品上市时间并降低投资风险的经验丰富的合约研发生产组织 (CDMO)。因此，製药生物技术产业对 CDMO 设计和生产产品的需求正在呈指数级增长。

mRNA 治疗合约开发和受託製造厂商市场亮点

  • 病毒疫苗领域将在 2024 年占据最大份额。该领域的成长可归因于用于治疗病毒感染（COVID-19）的各种疫苗的可用性和推出的增加。
  • 由于感染疾病率不断上升、mRNA 疫苗相较于传统疫苗的许多优势、新兴的临床研究和管道分析，以及製药公司之间生产合作的不断加强和市场细分，预计感染疾病领域将在 2024 年占据最大的市场占有率。
  • 生物技术最终用途领域将主导市场，到 2024 年将占 62.34% 以上的份额。该领域的成长受到日益增多的策略性倡议的推动，例如与 CDMO 建立合作伙伴关係并合作生产 mRNA 疫苗。
  • 预计亚太地区mRNA疗法受託製造厂商市场在预测期内将实现显着的复合年增长率。由于印度和中国等开发中国家製药公司和受託製造厂商数量的不断增加，亚太地区在不久的将来很可能超越欧洲和北美。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章 mRNA 治疗合约开发与受託製造厂商的市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 定价模式分析
  • 科技
  • 市场分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析
    • COVID-19影响分析

第四章 mRNA 治疗合约开发和受託製造厂商市场：按适应症的估计和趋势分析

  • mRNA 治疗合约开发与受託製造厂商市场（按适应症）：细分仪表板
  • mRNA 治疗合约开发与受託製造厂商市场（按适应症）：波动分析
  • 依适应症，2021-2033年
  • 感染疾病
  • 代谢和遗传疾病
  • 心臟和脑血管疾病

第五章 mRNA 治疗合约开发和受託製造厂商市场：按应用进行的估计和趋势分析

  • mRNA 治疗合约开发与受託製造厂商市场（按应用）：细分仪表板
  • mRNA 治疗合约开发与受託製造厂商市场（按应用）：波动分析
  • 按应用，2021-2033 年
  • 病毒疫苗
  • 蛋白质替代疗法
  • 癌症免疫治疗

第六章 mRNA 治疗合约开发和受託製造厂商市场：按最终用途分類的估计和趋势

  • mRNA 治疗合约开发和受託製造厂商市场（按最终用途）：细分仪表板
  • mRNA 治疗合约开发与受託製造厂商市场（以最终用途）：变异分析
  • 依最终用途，2021-2033 年
  • 生技公司
  • 製药公司
  • 政府及学术研究机构

第七章 mRNA 治疗合约开发和受託製造厂商市场：按地区估计和趋势分析

  • 区域市场仪表板
  • 2024 年及 2033 年区域市场占有率分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 市场参与企业分类
  • 2024 年公司市场占有率/估值分析
  • 公司简介
    • Danaher（Aldevron）
    • Biomay AG
    • Bio-Synthesis, Inc.
    • eTheRNA
    • Kaneka Eurogentec SA
    • TriLink BioTechnologies
    • ApexBio Technology
    • BioNTech SE
    • Biocina
    • Lonza
    • Recipharm AB
    • Novo Holdings（Catalent, Inc.）
    • Samsung Biologics
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is estimated to reach USD 14.75 billion by 2033, expanding at a CAGR of 15.22% from 2025 to 2033, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

  • The viral vaccines segment accounted for the largest share in 2024. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • The infectious diseases segment held the largest market share in 2024 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
  • The biotech companies end-use segment dominated the market and accounted for a share of more than 62.34% in 2024. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
  • The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a significant CAGR over the forecast period. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Value-Chain-Based Sizing & Forecasting
    • 1.7.3. Multivariate Model Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rapid adoption of mRNA in vaccine development
      • 3.2.1.2. Multiple research efforts on mRNA therapeutics
      • 3.2.1.3. Major funding for mRNA research
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Availability of low-cost substitute therapies
      • 3.2.2.2. High research cost
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Force Analysis
    • 3.5.2. PESTEL by SWOT Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Segment Dashboard
  • 4.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Movement Analysis
  • 4.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 4.4. Infectious Diseases
    • 4.4.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Metabolic & Genetic Diseases
    • 4.5.1. Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Cardiovascular & Cerebrovascular Diseases
    • 4.6.1. Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Segment Dashboard
  • 5.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Movement Analysis
  • 5.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
  • 5.4. Viral Vaccines
    • 5.4.1. Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Protein Replacement Therapies
    • 5.5.1. Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cancer Immunotherapies
    • 5.6.1. Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Segment Dashboard
  • 6.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Movement Analysis
  • 6.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 6.4. Biotech Companies
    • 6.4.1. Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pharmaceutical companies
    • 6.5.1. Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Government & Academic Research Institutes
    • 6.6.1. Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Australia
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Biomay AG
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Bio-Synthesis, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. eTheRNA
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Kaneka Eurogentec S.A.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. TriLink BioTechnologies
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. ApexBio Technology
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. BioNTech SE
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Biocina
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Lonza
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Recipharm AB
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Novo Holdings (Catalent, Inc.)
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Samsung Biologics
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 4. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 5. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 6. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 7. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 9. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 10. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 11. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 12. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 13. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 14. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 15. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 16. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 17. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 18. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 19. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 20. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 21. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 22. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 23. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 24. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 26. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 27. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 28. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 29. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 30. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 31. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 33. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 34. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 35. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 36. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 37. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 38. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 39. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 40. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 41. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 42. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 43. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 44. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 45. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 46. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 47. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 51. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 52. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 53. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 54. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 55. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 56. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 57. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 58. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 59. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 60. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 61. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 62. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 63. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 64. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 65. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 66. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 67. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 68. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 69. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 70. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 71. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 72. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 73. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 74. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 75. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 76. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 77. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 78. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 79. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 83. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 84. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 85. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 86. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 89. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 90. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 91. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 92. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 93. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 94. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 95. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication outlook and key takeaways
  • Fig. 20 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication movement analysis
  • Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application outlook and key takeaways
  • Fig. 25 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application movement analysis
  • Fig. 26 Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 30 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use movement analysis
  • Fig. 31 Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Regional Marketplace: Key Takeaways
  • Fig. 35 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key company categorization
  • Fig. 87 Service heat map analysis
  • Fig. 88 Strategic framework